secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001104659-25-061397
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma to merge with OrthoCellix; pre-merger holders to own ~10% of combined company
--------------------------------------------------------------------------------

- Carisma (CARM) enters merger with Ocugen subsidiary OrthoCellix; Merger Sub to merge into OrthoCellix, which becomes wholly owned subsidiary.
- Pre-merger Carisma stockholders will own ~10% of combined company; Ocugen/OrthoCellix stockholders and Concurrent Investment investors will own ~90%, on fully-diluted basis.
- Expected Concurrent Investment of at least $25M; Ocugen commits to purchase at least $5M of Carisma common stock at or immediately after closing.
- Exchange ratio based on OrthoCellix valuation of $135M (less any shortfall in Concurrent Investment) and Carisma valuation of $15M (adjusted for net cash).
- CVR Agreement grants pre-merger Carisma stockholders contingent cash payments from future disposition of legacy assets, including Moderna collaboration; no assurance of payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925061397/0001104659-25-061397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925061397/tm2518620d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-061397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer